{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:41Z","timestamp":1786120301417,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/ico.0b013e318211400a","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T20:01:48Z","timestamp":1317758508000},"page":"90-91","source":"Crossref","is-referenced-by-count":30,"title":["Certolizumab Pegol Therapy for Rheumatoid Arthritis\u2013Associated Scleritis"],"prefix":"10.1097","volume":"31","author":[{"given":"Paul S","family":"Tlucek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald U","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210204","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0889-857X(05)70201-5","article-title":"The epidemiology of rheumatoid arthritis.","volume":"27","author":"Gabriel","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"R2-18-20210204","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard.62.8.722","article-title":"Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years.","volume":"62","author":"Turreson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R3-18-20210204","first-page":"210","article-title":"Emerging therapeutics for rheumatoid arthritis.","volume":"66","author":"Bingham","year":"2008","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"R4-18-20210204","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/s10165-010-0277-7","article-title":"Aspects of TNF inhibitor therapy in rheumatoid arthritis.","volume":"20","author":"Nam","year":"2010","journal-title":"Mod Rheumatol"},{"key":"R5-18-20210204","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R6-18-20210204","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R7-18-20210204","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/rheumatology\/keh635","article-title":"Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy.","volume":"44","author":"Ashok","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"R9-18-20210204","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.ICL.0000092064.05514.04","article-title":"Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration.","volume":"31","author":"Hernandez-Illas","year":"2004","journal-title":"Eye Contact Lens"},{"key":"R10-18-20210204","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MAJ.0b013e3180318fbc","article-title":"Tumor necrosis factor antagonists: preliminary evidence for any emerging approach in the treatment of ocular inflammation.","volume":"27","author":"Theodossiadis","year":"2007","journal-title":"Retina"},{"key":"R11-18-20210204","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"R12-18-20210204","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R13-18-20210204","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomized controlled trial.","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00003226-201201000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:18:05Z","timestamp":1786047485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-201201000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e318211400a","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}